Contact
Header_1077x260px_About_Profil.jpg

First drug approved for NASH

BfArM speeds up the approval process for clinical trials in Germany

Correct interpretation of key CGM metrics

GLP-1 based drugs: Could Elon Musk’s weight loss weapon help us, too?

Profil's scientific publications in 2023 - an overview

A novel long-acting Amylin analogue for the management of obesity

CTR 536/2014: First approvals and our experience with CTIS (Part 3)

Corporate Social Responsibility in Clinical Trials

Unique Device Identifier, UDI, examplified by Profil’s class IIb medical device “ClampArt” (Part II)

Unique Device Identifier, UDI, examplified by Profil’s class IIb medical device “ClampArt” (Part I)